|Table of Contents|

Single-center efficacy analysis based on pediatric Wilms tumor-2016 diagnosis and treatment regimen(38 cases)

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 04
Page:
685-689
Research Field:
Publishing date:

Info

Title:
Single-center efficacy analysis based on pediatric Wilms tumor-2016 diagnosis and treatment regimen(38 cases)
Author(s):
XU Jixin; DUAN Yongtao; LI Yange; ZHU Yingchao; LIU Wei
Department of Hematology and Oncology，Children's Hospital Affiliated to Zhengzhou University，Henan Children's Hospital，Zhengzhou Children's Hospital，Henan Zhengzhou 450000，China.
Keywords:
Wilms tumor; children; chemotherapy regimen; prognosis
PACS:
R737.11
DOI:
10.3969/j.issn.1672-4992.2022.04.025
Abstract:
Objective:To explore the clinical efficacy of children with Wilms tumor by adopting children WT-2016-protocol in single center.Methods:The clinical data of Wilms tumor treated with CCCG-WT-2016 protocol from February 2017 to March 2020 were retrospectively,their clinical features and therapeutic prognosis were analyzed retrospective.3-year event-free survival (EFS) rate and overall survival (OS) rate of each group were analyzed by Kaplan-Meier curve method.Results:A total of 38 children(27 boys and 11 girls) were included,with a median age of 22.0 (5.2~84.0) months.The pathological classification were 33 cases of favorable histology (FH) type including 2 cases of teratoma-like Wilms tumor,and 1 case of unfavorable histology (UFH) type,4 cases clear cell sarcoma of kidney.The children were followed up until March 2021,median follow-up time was 30.5（11.2～48.5）months.There were 2 deaths,of which 1 was due to recurrence,1 was bilateral Wilms tumor which has not remission,and died of tumor progression.There were 3 cases of recurrence,including 2 cases of metastasis to the lungs (1 case of in-situ tumor recurrence with pulmonary metastasis) and 1 case of multiple tumor metastases in the abdominal and pelvic cavity.The 3-year event-free survival (EFS) rate of FH group was（84.6±9.2）%.Among them,EFS rate in stage Ⅰ and Ⅱ was 100%,EFS rate in stage Ⅲ,stage Ⅳ and stage V were （85.7±13.2）%,（80.0±17.9）% and （66.7±27.2）% respectively.The Log-Rank test showed that there was no statistical significance in prognosis of children between stage Ⅰ+Ⅱ and stage Ⅲ+Ⅳ+Ⅴ(χ2＝2.691，P=0.101).The 3-year overall survival (OS) rate of FH group was （91.7±8.0）%.Among them,OS rate in stage Ⅰ,Ⅱ and Ⅲ was 100%,OS rate in stage Ⅳ and stage V were (81.1±9.3)% and （70.0±8.5)% respectively.The Log-Rank test showed that there was no statistical significance in prognosis of children between stage Ⅰ+Ⅱ+Ⅲ and stage Ⅳ+Ⅴ (χ2＝2.380,P=0.123).In 4 cases of clear cell sarcoma of kidney,the 3-year EFS rate was (75.0±21.7)%,and the cumulative OS rate was 100%.Conclusion:Treating patients with WT by using CCCG-WT-2016 protocol according to clinical stage can achieve very high 3-year EFS rate and OS rate.

References:

[1]BROK J,MAVINKURVE-GROOTHUIS AMC,DROST J,et al.Unmet needs for relapsed or refractory Wilms tumour:Mapping the molecular features,exploring organoids and designing early phase trials - A collaborative SIOP-RTSG,COG and ITCC session at the first SIOPE meeting［J］.Eur J Cancer,2021,144:113-122.
[2]CUNNINGHAM ME,KLUG TD,NUCHTERN JG,et al.Global disparities in Wilms tumor［J］.J Surg Res,2019,247:34-51.
[3]MILFORD K,DECOTIIS K,LORENZO A,et al.Wilms tumor:A review of the current surgical controversies［J］.Transl Androl Urol,2020,9(5):2382-2392.
[4]中国抗癌协会小儿肿瘤专业委员会.儿童肾母细胞瘤诊断治疗建议（CCCG－WT－2016）［J］.中华儿科杂志,2017,55(2):90-94. Pediatric Oncology Committee of Chinese Anti-Cancer Association.Diagnosis and treatment of pediatric Wilms tumor (CCCG-WT-2016)［J］.Chinese Journal of Pediatrics,2017,55(2):90-94.
[5]KO EY,RITCHEY ML.Current management of Wilms' tumor in children［J］.J Pediatr Urol,2009,5(1):56-65.
[6]BHUTANI N,KAJAL P,SHARMA U.Many faces of Wilms tumor:Recent advances and future directions［J］.Ann Med Surg (Lond),2021,64(3):102202.
[7]HEUVEL-EIBRINK MM,TINTEREN H,BERGERON C,et al.Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol,a report of the SIOP Renal Tumour Study Group (SIOP-RTSG)［J］.Eur J Cancerr,2015,51(4):498-506.
[8]HUANG J,ZHANG Y,ZHEN ZJ,et al.The prognosis of prechemotherapy blastemal predominant histology subtype in Wilms tumor:A retrospective study in China［J］.Pediatr Blood Cancer,2020,67(11):e28567.
[9]PASQUALINI C,FURTWNGLER R,TINTEREN HV,et al.Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol:A report of the SIOP Renal Tumour Study Group［J］.Eur J Cancer,2020,128:38-46.
[10]KOSHINAGA T,TAKIMOTO T,OKITA H,et al.Blastemal predominant type Wilms tumor in Japan:Japan Children's Cancer Group［J］.Pediatr Int,2019,61(4):351-357.
[11]DRYSDALE H,FAWKNER-CORBETT D,SOLOMON Z,et al.Bilateral Wilms' tumour:An international comparison of treatments and outcomes［J］.J Pediatr Surg,2021,56(9):00090-7.
[12] ALDRINK JH,HEATON TE,DASGUPTA R,et al.Summary article:Update on Wilms tumor［J］.J Pediatr Surg,2019,54(3):390-397.
[13] 解鲁璐,董岿然.肾母细胞瘤复发的诊疗进展［J］.中华小儿外科杂志,2020,41(06):571-576. XIE LL,DONG WR.Progress in the diagnosis and treatmentof recurrent Wilms tumours［J］.Chin J Pediatr Surg,2020,41(06):571-576.
[14]EHRLICH PF,CHI YY,CHINTAGUMPALA MM,et al.Results of treatment for patients with multicentric or bilaterally predisposed unilateral Wilms tumor (AREN0534):A report from the Children's Oncology Group［J］.Cancer,2020,126(15):3516-3525.
[15]VENKATRAMANI R,CHI YY,COPPES MJ,et al.Outcome of patients with intracranial relapse enrolled on national Wilms Tumor Study Group clinical trials［J］.Pediatr Blood Cancer,2017,64(7):e26406.
[16]DIX DB,SEIBEL NL,CHI YY,et al.Treatment of stage IV favorable histology Wilms tumor with lung metastases:A report from the children's oncology group AREN0533 study［J］.J Clin Oncol,2018,36(16):1564-1570.
[17] DIX DB,FERNANDEZ CV,CHI YY,et al.Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology Wilms tumor:A Children's Oncology Group AREN0532 and AREN0533 study report［J］.J Clin Oncol,2019,37(30):2769-2777.
[18] KITAMURA E,COWELL JK,CHANG CS,et al.Variant profiles of genes mapping to chromosome 16q loss in Wilms tumors reveals link to cilia-related genes and pathways［J］.Genes Cancer,2020,11(3-4):137-153.
[19] NELSON MV,HEUVEL-EIBRINK MM,GRAF N,et al.New approaches to risk stratification for Wilms tumor［J］.Curr Opin Pediatr,2021,33(1):40-48.
[20]CHAGTAI T,ZILL C,DAINESE L,et al.Gain of 1q as a prognostic biomarker in Wilms tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 trial:a SIOP renal tumours biology consortium study［J］.J Clin Oncol,2016,34(26):3195-3203.
[21] HE CJ,QIN H,TANG HZ,et al.Comprehensive bioinformatics analysis of the TP53 signaling pathway in Wilms' tumor［J］.Ann Transl Med,2020,8(19):1228.

Memo

Memo:
National Natural Science Foundation of China(No.22007086）；国家自然科学基金(编号:22007086)；河南省郑州市小儿血液研究重点实验室建设经费项目（编号:111PYFZX155）
Last Update: 1900-01-01